European Pharmaceutical Review’s podcasts interview some of the leading experts and scientists about the latest developments in the pharmaceutical and life science sectors.
How is the implementation of artificial intelligence, machine learning and virtual reality shaping the microbiology lab of the future? What do these innovations mean for personnel? Find out in this episode with AstraZeneca...
As Pharma 4.0 becomes a reality, a diverse array of technologies have emerged to enhance industrial processes, from the internet of things to artificial intelligence, machine learning and virtual reality. In this episode AstraZeneca's Sophie Bailes, Associate Director for Digital Transformation and Miriam Guest, Principal Microbiologist, Pharmaceutical Technology & Development, share how these innovations are changing the the microbiology lab and aseptic manufacturing practices for the future.
Breast cancer drug development
What unmet need remains in breast cancer and how is drug development helping tackle these challenges? Tune in to this episode with Daiichi Sankyo to find out more.
Despite therapeutic advancement over the last few years, unmet need in breast cancer still remains. In this podcast, Professor Dr Markus Kosch, Head, Oncology Business Division Europe at Daiichi Sankyo, discusses the challenges associated with breast cancer treatment and some of the recent therapeutic developments that may help overcome them - highlighting the potential role of antibody-drug conjugates (ADCs).
QC spectroscopy compliance
Discover the common compliance concerns encountered when using spectroscopy instruments for QC, as well as how to rectify them in this episode with Agilent Technologies.
While we all know regulatory compliance is crucial, it can be challenging to meet the expectations within the highly regulated pharmaceutical industry. With spectroscopy instruments being a crucial pharmaceutical analysis tool, and their applications across the pharma industry growing, in this episode Agilent Technologies' Julia Griffen, Product Manager Raman Products and Garry Wright, European Laboratory Compliance Specialist, highlight some of the common compliance issues companies are facing when leveraging spectroscopy for QC and what to do to overcome them.
Digital twins in R&D
Tune in to discover how and why digital twins are being developed and used in pharmaceutical development and manufacturing.
As the industry works to establish interconnectivity leveraging automation, machine learning and real-time data in the transition to Pharma 4.0, digital twins have emerged as a solution to increase productivity and efficiency in drug development and manufacturing, while also enhancing quality. In our latest episode, Loredana Vagaggini, Senior Manager Principal Product Owner, Vx Tech R&D at GSK discusses the use of digital twins in pharmaceutical development and manufacturing.
Developing vaccine technologies
Why is vaccine manufacturing becoming more biological? How could Generalized Modules for Membrane Antigens (GMMA) enhance vaccinology? What developments have there been in adjuvant systems? Discover all this and more in this podcast with GSK experts.
With COVID-19 having intensified focus on vaccine development over the past few years, in this podcast we are exploring how manufacturing and formulation of vaccines has advanced and some promising technologies for the future. For this episode, European Pharmaceutical Review's Hannah Balfour is joined by two representatives from GSK: Giulia Giordano, PhD, Vaccine Development Leader, and Professor Mark Doherty, Senior Manager of Global Medical Affairs, Vaccines.
3D printing pharmaceuticals – Sheng Qi, Simon Gaisford, Clive Roberts
The idea of personalised medicine has been gaining interest in recent years as the drug development and healthcare industries seek to reduce side effects, improve adherence, and thus patient outcomes. As a potential enabler of personalised oral solid dosage forms (OSDs), three-dimensional (3D) printing has garnered significant interest. But despite a surge in research over the last decade, following patents for 3D printers expiring in 2009, so far just one pharmaceutical manufactured using 3D printing has been approved by regulators, Spritam® (levetiracetam), back in 2015. To find out about recent developments in the field, the major hurdles stalling the widespread implementation of 3D printing in commercial manufacturing and more, European Pharmaceutical Review's Hannah Balfour spoke with Sheng Qi, Professor of Pharmaceutical Material Science and Technology at the University of East Anglia, Simon Gaisford, Professor of Pharmaceutics in the University College London (UCL) School of Pharmacy, and Clive Roberts, Chair of Pharmaceutical Nanotechnology at the University of Nottingham.